Mom & Daughter lab case study comparison tells the story of lipids and why it is pathological to live with high lipids.

The Mechanism: Estrogen-Dependent Regulation of LDL Clearance

The elevation of serum Low-Density Lipoprotein (LDL) cholesterol during the menopausal transition is primarily driven by the withdrawal of estradiol, which plays a critical role in hepatic lipid metabolism through two primary molecular pathways:

1. Transcriptional Upregulation of LDLR

In a premenopausal state, estrogen binds to hepatic estrogen receptors (primarily ER-alpha). This complex acts as a transcription factor that enhances the expression of the LDLR gene. This results in a high density of LDL Receptors (LDLR) on the surface of hepatocytes (liver cells). These receptors are responsible for binding circulating LDL particles and removing them from the bloodstream via endocytosis.

2. Inhibition of the PCSK9 Pathway

Estrogen serves as a natural inhibitor of PCSK9. Under normal conditions, PCSK9 binds to the LDL receptor and marks it for degradation inside the cell, preventing the receptor from being recycled back to the cell surface.

With Estrogen: PCSK9 activity is suppressed, allowing LDL receptors to be recycled many times, maintaining high "clearance capacity."

Post-Menopause: As estrogen levels decline, PCSK9 levels rise. This leads to increased degradation of the existing LDL receptors.

The Pathophysiological Result

The combination of decreased receptor production and increased receptor destruction creates a "clearance bottleneck." Even if dietary cholesterol intake remains constant, the residence time of LDL particles in the plasma increases. This prolonged circulation time not only raises the measured LDL levels on a standard lipid panel but also increases the opportunity for these particles to undergo oxidation, a key step in the development of atherosclerosis.​

The solution? Optimally dose estradiol or use new medicines like Repatha to lower PSK9.

#antiagingmedicine is #lipidology